Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from Chardan Capital

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price target indicates a potential upside of 52.91% from the stock’s current price. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2025 earnings at ($0.30) EPS.

ABUS has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. StockNews.com lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Performance

Arbutus Biopharma stock opened at $3.27 on Friday. The business’s fifty day moving average is $3.33 and its two-hundred day moving average is $3.58. The firm has a market cap of $619.64 million, a P/E ratio of -7.60 and a beta of 1.93. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.20 million. On average, equities research analysts predict that Arbutus Biopharma will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Arbutus Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Intech Investment Management LLC bought a new position in Arbutus Biopharma in the third quarter valued at approximately $142,000. Charles Schwab Investment Management Inc. boosted its position in shares of Arbutus Biopharma by 218.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after purchasing an additional 831,663 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arbutus Biopharma by 453.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 30,723 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Arbutus Biopharma during the third quarter worth $754,000. Finally, Rockefeller Capital Management L.P. bought a new stake in Arbutus Biopharma in the third quarter valued at about $243,000. 43.79% of the stock is owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.